Board of Directors

John L. Bishop

Mr. Bishop joined us as Chief Executive Officer and as a director in April 2002. Mr. Bishop served as President and a director of Vysis, a genomic disease management company from 1993 to 2002 and as Chief Executive Officer from 1996 to March 2002. From 1991 until November 1993, Mr. Bishop was Chairman and Chief Executive Officer of MicroProbe Corporation, a biotechnology company and, from 1987 until 1991, of Source Scientific Systems, a biomedical instrument manufacturing company. From 1984 to 1986, Mr. Bishop was President and Chief Operating Officer of Gen-Probe, Inc. From 1968 to 1984, Mr. Bishop held various management positions with American Hospital Supply Company and its affiliates, including a three-year assignment in Japan as an Executive Vice President and Chief Executive Officer of International Reagents Corp., a joint venture between American Hospital Supply Company and Green Cross Corporation.

Cristina H. Kepner

Ms. Kepner joined us as a director in May 1998 and was named Lead Independent Director in February 2013. She was with Invemed from 1978 to 2000, where she served in a variety of capacities. Prior to retiring from Invemed Associates, LLC in December 2000, Ms. Kepner served as Executive Vice President and Corporate Finance Director. Ms. Kepner served as a director of Monogram Biosciences, Inc. from May 1996 until August 2009, when it was acquired by Laboratory Corporation of America Holdings, and as a director of Quipp, Inc. from January 1995, including Chairman of the board of directors from April 2004, until June 2008, when it was acquired by Illinois Tool Works Inc.

Thomas D. Brown

Mr. Brown joined us as a director in February 2006. Mr. Brown joined Abbott Laboratories in 1974 as a sales representative in the Company's Diagnostics Division (ADD). From 1977 through 2002, he held numerous sales, marketing, and general management positions of increasing responsibility within ADD. In 1985 he assumed the position of Director of Sales and in 1986 was promoted to Divisional Vice President of U.S. Sales. In 1987 he was named Divisional Vice President and General Manager, Western Hemisphere Commercial Operations and in 1992 he was named Divisional Vice President, Commercial Operations. He was elected Corporate Vice President Worldwide Diagnostic Commercial Operations in 1993. In 1998, Mr. Brown was named Senior Vice President and President Diagnostics Division, a position held until his retirement from Abbott Labs in 2002. Mr. Brown holds a Bachelor of Arts degree from the State University of New York at Buffalo. He also currently serves on the Board of Directors for Quidel Corporation and Stericycle.

Robert J. Easton

Mr. Easton joined us as a director in January 2002. A recognized strategy consultant in healthcare and an authority on clinical diagnostics, Mr. Easton is a co-founder and Chairman of Scisive Consulting LP, a management consulting firm specializing in evaluation and planning for pharmaceutical and medical device companies. Earlier, he was Managing Director of IBM Healthcare Consulting and President of The Wilkerson Group. In addition to his 30 years in management consulting, Mr. Easton has 12 years of managerial experience in sales, marketing, planning, engineering, and operations roles with the industrial gas and medical products divisions of Union Carbide Europe. He currently serves as Chairman of Gilda's Club of New York City and serves on the Boards of New York Biotech Association and the Global Cardiovascular Innovation Center at Cleveland Clinic. Other recent Board experience includes CollaGenex Pharmaceuticals and Apex Bioventures.

Thomas L. Gutshall

Mr. Gutshall is a co-founder of Cepheid and has served as Chairman of the Board since August 1996. From August 1996 until April 2002, he also served as our Chief Executive Officer. From January 1995 to August 1996, he was President and Chief Operating Officer of CV Therapeutics. From 1989 to 1994, he was Executive Vice President at Syntex Corporation and a member of the Pharmaceutical Executive Committee. His responsibilities while at Syntex included managing Syva Company, Syntex Agribusiness, Pharmaceutical and Chemical Operations and Services, Syntex Pharmaceutical Intl. Ltd. and Environmental Health and Safety. Mr. Gutshall currently serves as a director of Satoris Corporation.

Dean Morton

Mr. Morton joined us as a director in July 1997. Mr. Morton has been retired for the past thirteen years. He was Executive Vice President, Chief Operating Officer and a director of Hewlett-Packard Company where he was employed from 1960 to 1992. Mr. Morton currently serves on the Board of Monterey Bay Aquarium Research Institute and Center for Excellence in Non-Profits.

David H. Persing, M.D., Ph.D.

Dr. Persing first joined us as a director in May 2004, and became our Executive Vice President and Chief Medical and Technology Officer in August 2005. From 1999 to 2005, Dr. Persing was Senior Vice President and Chief Scientific Officer at Corixa Corporation, a Seattle-based biotechnology company, until its acquisition by GlaxoSmithKline. Prior to that he was a member of the Clinical and Research Faculty in the Department Laboratory Medicine and Pathology at the Mayo Clinic in Rochester, Minnesota where he developed several extramurally funded research programs in infectious diseases. From 1992 to 1999 he established and directed the Mayo Molecular Microbiology Laboratory was one of the first reference laboratories to offer cutting-edge molecular diagnostic testing on a worldwide basis. He has authored over 270 peer-reviewed articles including frequently cited papers in the New England Journal of Medicine, Science, PNAS. He served as Editor in Chief for four leading textbooks on Molecular Diagnostics, the most recent of which was released in January 2011. Dr. Persing received his MD and PhD (Genetics) degrees from the University of California, San Francisco in 1988 and completed his clinical pathology residency training at the Yale School of Medicine in 1990.

Hollings C. Renton

Mr. Renton joined us as a director in March 2000. Mr. Renton retired from Onyx Pharmaceuticals, Inc., a biopharmaceutical and biotherapeutics company, in March 2008, where he had served as a director beginning in April 1992, President and Chief Executive Officer beginning in March 1993 and Chairman of the Board beginning in June 2003. From 1991 to 1993, he served as President and Chief Operating Officer of Chiron Corporation, a pharmaceutical company, following its acquisition of Cetus Corporation. Prior to the acquisition, he served as President of Cetus Corporation from 1990 to 1991 and as Chief Operating Officer from 1987 to 1990. Mr. Renton also serves as a member of the Boards of Directors of Affymax, Inc., Rigel Pharmaceuticals and Special Olympics of Northern California.

Glenn D. Steele Jr., M.D., Ph.D.

Dr. Steele is President and Chief Executive Officer of Geisinger Health System. Dr. Steele previously served as the dean of the Biological Sciences Division and the Pritzker School of Medicine and as vice president for medical affairs at the University of Chicago, as well as the Richard T. Crane Professor in the Department of Surgery. Prior to that, he was the William V. McDermott Professor of Surgery at Harvard Medical School, president and chief executive officer of Deaconess Professional Practice Group, Boston, Mass., and chairman of the department of surgery at New England Deaconess Hospital (Boston, Mass.). Widely recognized for his investigations into the treatment of primary and metastatic liver cancer and colorectal cancer surgery, Dr. Steele is past Chairman of the American Board of Surgery. He serves on the editorial board of numerous prominent medical journals.

Dr. Steele received his bachelor’s degree in history and literature from Harvard University and his medical degree from New York University School of Medicine. He completed his internship and residency in surgery at the University of Colorado, where he was also a fellow of the American Cancer Society. He earned his Ph.D. in microbiology at Lund University in Sweden. He is a member of the Institute of Medicine of the National Academy of Sciences, serves as a member on the Roundtable on Value and Science-driven Healthcare, a fellow of the American College of Surgeons, the American Surgical Association, the American Society of Clinical Oncology, and past president of the Society of Surgical Oncology. He is a member of the Healthcare Executives Network and the Commonwealth Fund's Commission on a High Performance Health System. Dr. Steele serves on several boards including Bucknell University's Board of Trustees, Temple University School of Medicine's Board of Visitors, Premier Inc. (Chair), Weis Markets Inc., Wellcare Health Plans Inc., Cepheid's Board of Directors, The Hospital & Healthsystem Association of Pennsylvania (HAP) Board of Directors, and the Harvard Medical Faculty Physicians Board at Beth Israel Deaconess Medical Center.